Functional investigation of the human proteome is a major ‘post-genome’ challenge with profound significance in both basic and medical research, as well as for the biotechnology and pharmaceutical industries. The affinity proteomics approach to proteome analysis calls for systematic generation of binders, in principle against all genome-encoded proteins and their variant forms; the development and impact of proteomic research in the coming years will be critically dependent on the availability of such reagents.
The aim of AFFINOMICS is to initiate the generation of a proteome-wide binder collection and to this end the project integrates the expertise and technologies available in leading European centres in order to create an efficient pipeline for target and binder production, validation and quality control. AFFINOMICS will focus on generating comprehensive binder sets for protein kinases, protein tyrosine phosphatases, SH2-domain containing proteins, proteins with somatic or germline mutations in cancer and potential selected cancer biomarkers. As well as including the classically raised polyclonal and monoclonal antibodies, AFFINOMICS will make a strong effort towards technological improvements in molecular selection systems for recombinant binder formats, particularly automation and other processes to increase throughput and reduce cost.
AFFINOMICS is an EC FP7 Collaborative Project. Project Coordinator: Dr Mike Taussig, Protein Technology Group, The Babraham Institute, Cambridge, UK